Login / Signup

Vitamin D status and risk of infections after liver transplantation in the Swiss Transplant Cohort Study.

Peter W SchreiberHeike A Bischoff-FerrariKatia BoggianChristian van DeldenNatalia EnriquezThomas Hans FehrChristian GarzoniHans H HirschCédric HirzelOriol ManuelPascal MeylanLanja SalehMaja WeisserNicolas J Muellernull null
Published in: Transplant international : official journal of the European Society for Organ Transplantation (2018)
Increasing evidence indicates a role of vitamin D in the immune system affecting response to infections. We aimed to characterize the role of vitamin D status, i.e. deficiency [25-OH vitamin D (25-OHD) <50 nmol/l] and no deficiency (25-OHD ≥50 nmol/l) in incident infections after liver transplantation. In 135 liver transplant recipients, blood samples drawn at time of liver transplantation and 6 months afterwards were used to determine 25-OHD levels. Incident infections episodes were prospectively collected within the Swiss Transplant Cohort Study database. Poisson regression was applied to address associations between vitamin D status and incident infections. Vitamin D deficiency was common at time of transplantation and 6 months afterwards without a significant change in median 25-OHD levels. In univariable analyses, vitamin D deficiency was a risk factor for incident infections in the first 6 months post-transplant incidence rate ratio (IRR 1.52, 95% CI 1.08-2.15, P = 0.018) and for bacterial infections occurring after 6 up to 30 months post-transplant (IRR 2.29, 95% CI 1.06-4.94, P = 0.034). These associations were not detectable in multivariable analysis with adjustment for multiple confounders. Efforts to optimize vitamin D supplementation in liver transplant recipients are needed. Our data question the role of vitamin D deficiency in incident infections.
Keyphrases
  • cardiovascular disease
  • type diabetes
  • emergency department
  • risk factors
  • electronic health record
  • artificial intelligence
  • replacement therapy
  • quality improvement
  • cell therapy
  • adverse drug